MindRank Announces $52 Million Series B Financing
MindRank AI Ltd. has secured $52 million in Series B financing to propel its AI-driven drug research and development, focusing on its promising candidate MDR-001, a GLP-1 receptor agonist currently in Phase III trials in China. This funding is a significant milestone that underscores the growing confidence in AI's role in revolutionizing drug discovery. With this capital, MindRank aims to accelerate its innovative pipeline and solidify its position as a leader in the biotech space, potentially offering new treatment options and reshaping the future of pharmaceutical research.
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.